It was true 3 years ago, but is it still the case?

One of the problems with a lot of research is that it is out of date by the time it is published. The following example may be a classic case in point. And it has serious implications. … READ MORE …

The value in personalization of expectant management strategies

A recent and truly excellent review in Nature Reviews: Urology offers us a very thoughtful set of insights on the role of “expectant” and “conservative” management (i.e., active surveillance and watchful waiting) in the care of men with prostate cancer today. … READ MORE …

Selection of appropriate candidates for management with active surveillance

In this month’s issue of the Journal of Urology, Dr. Peter Carroll (of UCSF) and Dr. Mark Dall’Era (formerly of UCSF and now at UCDavis) have contributed an editorial entitled “What is the optimal way to select candidates for active surveillance of prostate cancer?” … READ MORE …

Expectant management is really “coming of age” in the USA

An excellent new review article in CA: A Cancer Journal of Clinicians, along with a research letter just published in the Journal of the American Medical Association (JAMA) have provided us with an important update on the value and the increasing acceptance of expectant management in the treatment of lower-risk forms of prostate cancer. … READ MORE …

In 2004-07 most Medicare-eligible men were getting radiation therapy for first-line treatment of prostate cancer

In a second article in the new journal JAMA Oncology, researchers at the University of California Los Angeles suggest that 58 percent of all relatively recent treatment for prostate cancer was being given by radiation therapy of some type, and that indolent prostate cancer was being significantly over-treated. … READ MORE …

The choice of active surveillance: patient and partner perceptions

Two recent papers in the journal Psycho-oncology offer us interesting insights into patients’ (and their partners’) current perceptions about the role of active surveillance in the management of low-risk, localized prostate cancer. … READ MORE …

What’s being presented at ASCO this year: III

Another interesting presentation being made at the ASCO annual meeting this year will be the first report on a series of nearly 400 patients who did not conform to what would normally be considered a series of sound criteria for low risk disease. These patients all elected, as individuals, to go on actiuve surveillance despite their higher than average risk for progression. … READ MORE …